Karen A. Spindler

Karen A. Spindler

Karen A. Spindler

Karen Spindler, a partner in Goodwin's Technology & Life Sciences Group, advises life sciences companies and investors on a variety of intellectual property transactions. She represents biotech and pharmaceutical clients in transactions involving intellectual property assets and has considerable experience structuring and negotiating collaboration, co-development, license, supply and manufacturing agreements. She also counsels financial investors and operating companies on complex intellectual property issues arising in the context of corporate transactions, including mergers, stock and asset purchases, divestitures, royalty agreements, leveraged buyouts and financing transactions.

Ms. Spindler has been recognized as one of the nation’s leading patent and technology licensing lawyers by Euromoney Legal Media Group, Intellectual Asset Management and Super Lawyers.

Professional Experience

Prior to joining Goodwin, Ms. Spindler was a partner in the Palo Alto and San Francisco offices of Kirkland & Ellis LLP.  Previously, she practiced at Skadden, Arps, Slate, Meagher & Flom LLP.


Ms. Spindler was recently named:

  • A "Life Sciences Star" by Euromoney Legal Media Group for licensing and collaboration expertise in the life sciences industry (every year since 2012).
  • One of the world's leading 1,000 patent practitioners by Intellectual Asset Management (IAM) (every year since 2012)
  • One of the world's leading 300 IP strategists by Intellectual Asset Management (IAM) (2015)
  • A "Rising Star in Intellectual Property" by Super Lawyers (every year since 2009).
Areas of Practice


Ms. Spindler has advised Fortune 500 biopharmaceutical companies, semiconductor manufacturers and computer technology providers, as well as leading private equity funds on a variety of intellectual property and licensing matters.

Representative Matters

Life Sciences Strategic Collaborations and M&A
  • Foundation Medicine in the collaboration agreements forming part of its strategic transaction with Roche of a total value in excess of $1 billion
  • Royalty Pharma in its $3.3 billion purchase of Ivacaftor royalty rights from the Cystic Fibrosis Foundation (the largest pharmaceutical royalty acquisition completed to date)
  • Royalty Pharma in its $415 million acquisition of royalty rights to alogliptin/trelagliptin products and Priligy® (dapoxetine) from Furiex Pharmaceuticals, Inc.
  • Blueprint Medicines in its strategic collaboration with Alexion Pharmaceuticals to advance kinase drug candidates in rare genetic diseases
  • Intellia Therapeutics in its exclusive collaboration with Novartis for the development of new CRISPR/Cas9-based therapies (the industry’s first CRISPR/Cas9 biotech-pharma deal)
  • Tetragenetics in its collaboration with MedImmune for a multi-target ion channel drug discovery program
  • Scholar Rock in its global research collaboration with Johnson & Johnson and Janssen Biotech for the discovery and development of novel biologic therapeutics for the treatment of autoimmune diseases and cancer
  • Teva Pharmaceutical Industries in its $3.2 billion acquisition of Auspex Pharmaceuticals
  • Onyx Pharmaceuticals in its $10.4 billion sale to Amgen
  • Several biopharmaceutical clients on licensing transactions involving early stage products
  • Clients on licensing intellectual property assets from universities and other academic entities

* Certain representative matters prior to joining Goodwin

Other Licensing and M&A/Private Equity
  • Enterprise server business division of Hitachi, Ltd. in connection with collaboration and supply agreements
  • Samsung Electronics Co., Ltd. in connection with patent acquisitions and complex strategic licensing transactions*
  • Private equity fund Thoma Bravo in its majority investment in SailPoint Technologies, and in connection with take-private and other leveraged buyout transactions (together with financing aspects of such transactions)
  • M&A clients on license compliance issues relating to open source software use in the product environment*

* Certain representative matters prior to joining Goodwin Procter



J.D., 2002
Santa Clara University School of Law
(magna cum laude; Order of the Coif)
B.S., 1996
Stanford University
(with Honors)



Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers